Background and Objective: Colorectal cancer is a high mortality cancer. Clinical data analysis plays a crucial role in predicting the survival of colorectal cancer patients, enabling clinicians to make informed treatment decisions. However, utilizing clinical data can be challenging, especially when dealing with imbalanced outcomes. This paper focuses on developing algorithms to predict 1-, 3-, and 5-year survival of colorectal cancer patients using clinical datasets, with particular emphasis on the highly imbalanced 1-year survival prediction task. To address this issue, we propose a method that creates a pipeline of some of standard balancing techniques to increase the true positive rate. Evaluation is conducted on a colorectal cancer dataset from the SEER database. Methods: The pre-processing step consists of removing records with missing values and merging categories. The minority class of 1-year and 3-year survival tasks consists of 10% and 20% of the data, respectively. Edited Nearest Neighbor, Repeated edited nearest neighbor (RENN), Synthetic Minority Over-sampling Techniques (SMOTE), and pipelines of SMOTE and RENN approaches were used and compared for balancing the data with tree-based classifiers. Decision Trees, Random Forest, Extra Tree, eXtreme Gradient Boosting, and Light Gradient Boosting (LGBM) are used in this article. Method. Results: The performance evaluation utilizes a 5-fold cross-validation approach. In the case of highly imbalanced datasets (1-year), our proposed method with LGBM outperforms other sampling methods with the sensitivity of 72.30%. For the task of imbalance (3-year survival), the combination of RENN and LGBM achieves a sensitivity of 80.81%, indicating that our proposed method works best for highly imbalanced datasets. Conclusions: Our proposed method significantly improves mortality prediction for the minority class of colorectal cancer patients.

We investigated the data-driven relationship between features in the tumor microenvironment (TME) and the overall and 5-year survival in triple-negative breast cancer (TNBC) and non-TNBC (NTNBC) patients by using Explainable Artificial Intelligence (XAI) models. We used clinical information from patients with invasive breast carcinoma from The Cancer Genome Atlas and from two studies from the cbioPortal, the PanCanAtlas project and the GDAC Firehose study. In this study, we used a normalized RNA sequencing data-driven cohort from 1,015 breast cancer patients, alive or deceased, from the UCSC Xena data set and performed integrated deconvolution with the EPIC method to estimate the percentage of seven different immune and stromal cells from RNA sequencing data. Novel insights derived from our XAI model showed that CD4+ T cells and B cells are more critical than other TME features for enhanced prognosis for both TNBC and NTNBC patients. Our XAI model revealed the critical inflection points (i.e., threshold fractions) of CD4+ T cells and B cells above or below which 5-year survival rates improve. Subsequently, we ascertained the conditional probabilities of $\geq$ 5-year survival in both TNBC and NTNBC patients under specific conditions inferred from the inflection points. In particular, the XAI models revealed that a B-cell fraction exceeding 0.018 in the TME could ensure 100% 5-year survival for NTNBC patients. The findings from this research could lead to more accurate clinical predictions and enhanced immunotherapies and to the design of innovative strategies to reprogram the TME of breast cancer patients.